J&J’s Janssen Biotech Invests in Microbiome Research with Second Genome Collaboration
By Heather Cartwright
Pharma Deals Review: Vol 2013 Issue 6 (Table of Contents)
Published: 26 Jun-2013
DOI: 10.3833/pdr.v2013.i6.1956 ISSN: 1756-7874
Section: Research & Development
Fulltext:
Abstract
In a first for the field, Johnson & Johnson’s Janssen Biotech has formed a strategic collaboration with start-up Second Genome to characterise therapeutic mechanisms in ulcerative colitis (UC) that are mediated by the microbiome, the bacterial ecosystem living in and on the human body...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS